Table 2 Studying the effect of CD38 expression % on mature B-cell lymphoma patients regarding demographic, hematological, and clinical characteristics:
From: Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
Mature B-cell lymphoma | CD38 Negative | CD38 Positive | P-value | |
|---|---|---|---|---|
No. = 42 | No. = 48 | |||
Age (years) | Mean ± SD | 56.5 ± 8.9 | 54.7 ± 18.8 | 0.563• |
Range | 40–69 | 23–80 | ||
Sex | Females | 12 (28.6%) | 13 (27.1%) | 0.875* |
Males | 30 (71.4%) | 35 (72.9%) | ||
Category/diagnosis | CLL | 32 (76.2%) | 16 (33.3%) | 0.000* |
B-NHL | 10 (23.8%) | 32 (66.7%) | ||
WBC (x103/ul) | Median (IQR) | 59 (27.3–117) | 50 (15.8–70) | 0.138‡ |
Range | 9.3–531 | 3.01–428 | ||
LYMPH (x103/ul) | Median (IQR) | 48 (20–97) | 38.5 (14–61) | 0.156‡ |
Range | 6–480 | 2–360 | ||
HB (g/dl) | Mean ± SD | 10.23 ± 2.91 | 9.26 ± 2.26 | 0.078• |
Range | 4.2 – 16.1 | 4.6 – 14 | ||
PLT (x103/ul) | Median (IQR) | 157 (90–233) | 98.5 (50–146) | 0.003‡ |
Range | 16–402 | 10–576 | ||
BM.LYM (%) | Mean ± SD | 76.14 ± 18.16 | 72.98 ± 20.46 | 0.443• |
Range | 21 – 98 | 10 – 97 | ||
P53 mutation | Negative Positive | 8 (72.7%) 3 (27.3%) | 7 (53.8%) 6 (46.2%) | 0.341* |
sPD-L1 (ng/L) | Median (IQR) | 116.7 (68.25–240) | 232.35 (153.75–452.75) | 0.000‡ |
Range | 21.51–1427 | 100.9–1600 | ||
sPD-1 (ng/L) | Median (IQR) | 97.74 (47–135) | 217.5 (156–661) | 0.000‡ |
Range | 19.38–680 | 110–1300 | ||
sADO (ng/ml) | Median (IQR) | 530 (343–614) | 835.5 (723–1332) | 0.000‡ |
Range | 73–777 | 553–1700 | ||
Risk stratification | Low | 13 (31.0%) | 9 (18.8%) | 0.095* |
Intermediate | 18 (42.9%) | 16 (33.3%) | ||
High | 11 (26.2%) | 23 (47.9%) | ||
